Table 5 Comparison of patient sex and age between serious and non-serious reports.
From: A pharmacovigilance analysis of post-marketing safety of durvalumab
Serious /Non-serious, n | P-value | OR(95%CI) | |
|---|---|---|---|
Gender | |||
Famale (Reference) | 2589/231 | P < 0.001 | - |
Male | 5492/268 | 1.83(1.52–2.19) | |
Age Group, years | |||
< 65 (Reference) | 2450/133 | - | |
65–74 | 2456/88 | P = 0.003 | 1.52(1.15−2.00) |
≥ 75 | 1466/57 | P = 0.038 | 1.40(1.02–1.92) |
